Shares of Seattle Genetics are soaring more than 10% this morning after the Bothell, Wash.-based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a… Read More
— Brad Porter, the longtime Amazon robotics leader, has surfaced as the first chief technology officer of Scale AI, a San Francisco-based company seeking to accelerate the development of artificial… Read More
Seattle Genetics today announced FDA approval for its drug Tukysa, also known as tucatinib, which fights aggressive breast cancers. Tucatinib is a daily pill that targets human epidermal growth factor… Read More
Microsoft and Amazon are the centerpieces of Seattle’s booming tech scene, and 2019 was a big year for both of them. Microsoft eclipsed a market capitalization of $1 trillion and… Read More
Shares of cancer drug maker Seattle Genetics soared more than 17 percent Monday morning following positive results for a new drug that fights aggressive breast cancers. Tucatinib is a daily… Read More
Chinook Therapeutics, a Vancouver, B.C.-based biotech company creating targeted therapies for kidney diseases, raised $65 million in a Series A financing round led by Versant Ventures with Apple Tree Partners… Read More
Seattle Genetics sold more than 8 million shares in a stock offering that brought in $575 million for the company before expenses and commissions. The Bothell, Wash.-based drugmaker said the… Read More
Seattle Genetics on Thursday reported higher-than-expected losses for the fourth quarter, sending shares down 8 percent in after-hours trading. Quarterly revenues came in at $175 million, above Wall Street expectations… Read More
Seattle Genetics’ star cancer drug Adcetris has won Food and Drug Administration approval for treatment of a fast-growing type of non-Hodgkin lymphoma. The approval comes after the drug showed better… Read More
In a management reshuffle at Chinese search engine giant Baidu, COO and Microsoft veteran Qi Lu is stepping down from his role, according to a report by the South China… Read More
Biotech company Seattle Genetics, which develops cancer treatments, reported mixed earnings results on Thursday, its first earnings report since it closed its $614 million acquisition of Cascadian Therapeutics. The company outperformed… Read More
Lisa Conquergood has taken quite a journey in the startup world. She was the chief marketing officer of photo-editing service Picnik when the startup was bought by Google. She then… Read More
On a chilly Monday morning in January, Seattle awoke to the news that one of its most promising companies, Juno Therapeutics, reached a deal to be acquired by biotech giant… Read More
Seattle Genetics, a Seattle-based biotechnology company that makes the cancer therapy Adcetris, beat Wall Street expectations in its 2017 earnings Thursday. The company announced $482.3 million in revenue for 2017,… Read More
Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the company’s small-molecule breast cancer treatment for about $614 million, or… Read More
Eric Dobmeier, the longtime COO at public biotech company Seattle Genetics, is stepping down from his role to become CEO at stealthy biotech startup Silverback Therapeutics, GeekWire has learned. Dobmeier will… Read More
Seattle Genetics, the maker of cancer drug Adcetris, beat analyst expectations by a noticeable margin in its third-quarter earnings, reported Thursday. The company brought in a revenue of $135.3 million… Read More
Seattle Genetics, a Bothell, Wash., based biotechnology company developing novel treatments for cancer, announced Monday that it has discontinued the late-stage trial of its treatment for blood cancers after finding… Read More
Seattle-based biotech company Seattle Genetics announced a revenue of $109 million for the first quarter of 2017 Thursday, narrowly beating analyst expectations of $103 million. The company’s stock climbed slightly… Read More
In December of last year, the FDA ordered three early clinical trials of one of Seattle Genetics’ cancer drugs put on hold. This morning, the company announced that hold has… Read More
Shares of Seattle Genetics fell nearly 15 percent on Tuesday after the U.S. Food and Drug Administration placed clinical holds on its SGN-CD33A drug for acute myeloid leukemia (AML). The company announced… Read More
Bothell-based Seattle Genetics and Tokyo-based Takeda Oncology announced the success of their phase 3 clinical trial of Adcetris today, an immunotherapy drug that treats lymphoma, a cancer of white blood cells. Fifty-six percent of patients in… Read More
Despite posting record sales of its cancer drug and beating analyst expectations for its fourth quarter earnings on Tuesday, shares of Seattle Genetics are down 7 percent today. Seattle Genetics… Read More
Shares of Seattle Genetics stumbled on Tuesday after the Bothell-based company announced a partnership to license the Antibody-Coupled T-cell Receptor (ACTR) technology from Cambridge, Mass.-based Unum Therapeutics. As part of the… Read More